Interestingly, prior to treatment with the menin inhibitor, ENL was significantly enriched over both the B-ALL-specific genes and GMP-like program in the 148752 B-ALL sample, and during treatment, in the 152985 AML sample, ENL was only significantly enriched over the GMP-like program (Fig. 7f). The gene discussed is MLLT1; the disease is acute lymphoblastic leukemia.